Biodistribution, Pharmacokinetics, and Dosimetry of 177Lu-, 90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass Effect.
about
Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms.New Insights in the Design of Bioactive Peptides and Chelating Agents for Imaging and Therapy in Oncology.Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects.The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model.International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New NomenclatureThe tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonist
P2860
Biodistribution, Pharmacokinetics, and Dosimetry of 177Lu-, 90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass Effect.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Biodistribution, Pharmacokinet ...... 7Lu-DOTATATE: The Mass Effect.
@en
Biodistribution, Pharmacokinet ...... 7Lu-DOTATATE: The Mass Effect.
@nl
type
label
Biodistribution, Pharmacokinet ...... 7Lu-DOTATATE: The Mass Effect.
@en
Biodistribution, Pharmacokinet ...... 7Lu-DOTATATE: The Mass Effect.
@nl
prefLabel
Biodistribution, Pharmacokinet ...... 7Lu-DOTATATE: The Mass Effect.
@en
Biodistribution, Pharmacokinet ...... 7Lu-DOTATATE: The Mass Effect.
@nl
P2093
P1476
Biodistribution, Pharmacokinet ...... 7Lu-DOTATATE: The Mass Effect.
@en
P2093
Damian Wild
Guillaume P Nicolas
Jens Kaufmann
Lisa McDougall
Melpomeni Fani
Rosalba Mansi
P304
P356
10.2967/JNUMED.117.191684
P407
P577
2017-04-27T00:00:00Z